Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359150 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 223
- Enrollment target
NCT01359150 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 223 participants.
The verdict
NCT01359150, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 223 participants
- Enrollment target
Study Summary
A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis receiving CP-690,550 with and Without background Methotrexate
Interventions
- DRUG placebo
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359150
The ClinicalTrials.gov registry entry for NCT01359150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01359150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359150 about?
NCT01359150 is a clinical study titled "A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo". A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis receiving CP-690,550 with and Without background Methotrexate
What is the current status of trial NCT01359150?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2011-09. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01359150?
The interventions under investigation include: placebo (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01359150?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.